ALNYLAM PHARMACEUTICALS, INC. Accrued Liabilities, Current
ALNYLAM PHARMACEUTICALS, INC. (ALNY) had Accrued Liabilities, Current of $1.10 billion as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-07-30
- 2026-06-30: Accrued Liabilities, Current $1.10B.
- 2025-12-31: Accrued Liabilities, Current $1.08B.
- 2025-09-30: Accrued Liabilities, Current $1.15B.
- 2025-06-30: Accrued Liabilities, Current $918.97M.
| Period end | Accrued Liabilities, Current | Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $1.10B 10-Q · filed 2026-07-30 | |
| 2025-12-31 | $1.08B 10-Q · filed 2026-07-30 | |
| 2025-09-30 | $1.15B 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $918.97M 10-Q · filed 2025-07-31 | |
| 2025-03-31 | $704.16M 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $793.69M 10-K · filed 2026-02-12 | $887.47M 10-K · filed 2025-02-13 |
| 2024-09-30 | $946.17M 10-Q · filed 2024-10-31 | |
| 2024-06-30 | $808.64M 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $698.87M 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $713.01M 10-K · filed 2025-02-13 | |
| 2023-09-30 | $713.09M 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $598.53M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $508.60M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $545.46M 10-K · filed 2024-02-15 | |
| 2022-09-30 | $510.58M 10-Q · filed 2022-10-27 | |
| 2022-06-30 | $421.24M 10-Q · filed 2022-07-28 | |
| 2022-03-31 | $355.94M 10-Q · filed 2022-04-28 | |
| 2021-12-31 | $395.17M 10-K · filed 2023-02-23 | |
| 2021-09-30 | $388.58M 10-Q · filed 2021-10-28 | |
| 2021-06-30 | $341.19M 10-Q · filed 2021-08-03 | |
| 2021-03-31 | $280.53M 10-Q · filed 2021-04-29 | |
| 2020-12-31 | $355.91M 10-K · filed 2022-02-10 | |
| 2020-09-30 | $295.26M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $211.19M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $183.22M 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $197.20M 10-K · filed 2021-02-11 | |
| 2019-09-30 | $177.95M 10-Q · filed 2019-10-31 | |
| 2019-06-30 | $138.80M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $106.87M 10-Q · filed 2019-05-02 | |
| 2018-12-31 | $112.72M 10-K · filed 2020-02-13 | |
| 2018-09-30 | $93.56M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $89.87M 10-Q · filed 2018-08-02 | |
| 2018-03-31 | $63.82M 10-Q · filed 2018-05-04 | |
| 2017-12-31 | $72.20M 10-K · filed 2019-02-14 | |
| 2017-09-30 | $51.26M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $43.82M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $31.84M 10-Q · filed 2017-05-05 | |
| 2016-12-31 | $42.12M 10-K · filed 2018-02-15 | |
| 2016-09-30 | $36.21M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $37.55M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $30.80M 10-Q · filed 2016-05-04 | |
| 2015-12-31 | $28.80M 10-K · filed 2017-02-15 | |
| 2015-09-30 | $18.44M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $17.76M 10-Q · filed 2015-08-07 | |
| 2015-03-31 | $14.43M 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $23.68M 10-K · filed 2016-02-12 | |
| 2014-09-30 | $19.80M 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $15.78M 10-Q · filed 2014-08-08 | |
| 2014-03-31 | $16.60M 10-Q · filed 2014-05-09 | |
| 2013-12-31 | $14.16M 10-K · filed 2015-02-13 | |
| 2013-09-30 | $15.39M 10-Q · filed 2013-11-07 | |
| 2013-06-30 | $8.49M 10-Q · filed 2013-08-09 | |
| 2013-03-31 | $9.09M 10-Q · filed 2013-05-07 | |
| 2012-12-31 | $11.56M 10-K · filed 2014-02-20 | |
| 2012-09-30 | $14.91M 10-Q · filed 2012-11-05 | |
| 2012-06-30 | $14.23M 10-Q · filed 2012-08-08 | |
| 2012-03-31 | $13.01M 10-Q · filed 2012-05-03 | |
| 2011-12-31 | $12.34M 10-K · filed 2013-02-19 | |
| 2011-09-30 | $12.23M 10-Q · filed 2011-11-03 | |
| 2011-06-30 | $11.38M 10-Q · filed 2011-08-03 | |
| 2011-03-31 | $12.05M 10-Q · filed 2011-05-05 | |
| 2010-12-31 | $11.12M 10-K · filed 2012-02-13 | |
| 2010-09-30 | $10.88M 10-Q · filed 2010-11-04 | |
| 2010-06-30 | $7.42M 10-Q · filed 2010-08-05 | |
| 2009-12-31 | $9.96M 10-K · filed 2011-02-18 | $9.83M 10-Q · filed 2010-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |